Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
Arvinas (ARVN) reported Q2 2026 revenue of $249.7M, up from $22.4M a year earlier, driven by FDA approval of VEPPANU and a licensing deal with Rigel. The FDA approved VEPPANU, the first PROTAC therapy, for advanced breast cancer. Arvinas licensed global rights to Rigel, generating $50M in milestone revenue and $62.5M in license revenue. The company expects three Phase 1 readouts in the next year. Cash reserves fell to $567.9M from $685.4M due to operational expenses.
How this was made
The 30-second read
Why it matters
The regulatory win validates the company's platform, provides immediate cash inflow, and may reshape the protein degrader market.
Market read
The approval creates a catalyst for ARVN and RIGL stocks and may influence broader biotech valuations.
What to watch
Potential competition from other degrader platforms and reimbursement uncertainties could limit upside.
Background
Arvinas announced its Q2 2026 results alongside the first FDA approval of a PROTAC therapy, VEPPANU, for advanced breast cancer.
Ticker impact
FDA approved Arvinas' PROTAC drug VEPPANU and licensed rights to Rigel, generating $112.6M in milestone revenue this quarter.
Expect a 15‑20% upside in the next few trading sessions.
First‑in‑class FDA nod for a PROTAC, sizable milestone payments, and strong guideline endorsement create immediate upside catalysts.
Rigel Pharmaceuticals received exclusive global development, manufacturing and commercialization rights for VEPPANU, adding $112.6M milestone revenue.
Potential 8‑12% share price gain as market prices in the new product rights.
The deal expands Rigel's oncology franchise, but execution risk and integration costs moderate the upside.
Market effects
Boosts biotech and oncology sectors as first PROTAC approval signals new therapeutic class viability.
Positive for US biotech investors, modest spillover to European partners.
Sets precedent for regulatory pathways of protein degraders worldwide.
Counterpoint
Milestone revenue may be offset by higher cash burn and execution risk on upcoming trials.
Key entities
- companyArvinas Inc.
Clinical‑stage biotech that developed VEPPANU, a first‑in‑class PROTAC.
- companyRigel Pharmaceuticals Inc.
Partner receiving exclusive rights to develop, manufacture, and commercialize VEPPANU.
- regulatorFDA
U.S. Food and Drug Administration that granted the first PROTAC approval.
